Overview

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus

Status:
Not yet recruiting

Trial end date:
2023-05-03

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to assess the safety and tolerability of multiple subcutaneous injections of HRS9531 in patients with type 2 diabetes mellitus who have suboptimal glycaemic control after conventional lifestyle or metformin intervention.

Phase:

Phase 1

Details

Lead Sponsor:

Fujian Shengdi Pharmaceutical Co., Ltd.

Treatments:

Dulaglutide